This Article Full Text (PDF) Other Versions of this Article: JVI.01876-07v1 82/3/1605    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Murakami, S. Articles by Kawaoka, Y. Search for Related Content PubMed PubMed Citation Articles by Murakami, S. Articles by Kawaoka, Y.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.01876-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Establishment of Canine RNA Polymerase I-Driven Reverse Genetics for Influenza A Virus: its Application for H5N1 Vaccine Production

Division of Virology, Department of Microbiology and Immunology, and International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Saitama, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin

^* To whom correspondence should be addressed. Email: horimoto{at}ims.u-tokyo.ac.jp. kawaoka{at}ims.u-yokyo.ac.jp.

	Abstract

In the event of a new influenza pandemic, vaccines whose antigenicities match circulating strains must be rapidly produced. Here, we established an alternative reverse genetics system for influenza virus using the canine polymerase I (PolI) promoter sequence that works efficiently in the Madin-Darby canine kidney cell line - a cell line approved for human vaccine production. Using this system, we were able to generate H5N1 vaccine seed viruses more efficiently than can be achieved with the current system that uses the human PolI promoter in African green monkey Vero cells, thus improving pandemic vaccine production.